GlassScriptPhysician profile
Nicole Zacour
NPI 1790089100
$9,557.31
in general payments reported to CMS, 2019-2025
30 companies · $2,679 in 2025
The $2,679 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $1,726 · 2023: $1,913 · 2024: $2,384 · 2025: $2,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,827 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,826.68 |
| Education | $149.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,780.85 | 2021-2025 | |
| Amgen INC. | $1,595.23 | 2021-2025 | Evenity, Enbrel, Tavneos |
| Janssen Biotech, INC. | $1,509.98 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $991.34 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $693.32 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $570.10 | 2021-2025 | Orencia |
| Pfizer INC. | $500.18 | 2021-2025 | |
| Lilly USA, LLC | $358.54 | 2021-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $252.19 | 2023-2025 | |
| Glaxosmithkline, LLC. | $237.14 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $213.99 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $141.95 | 2022-2023 | Acthar |
| Radius Health, INC. | $126.05 | 2021-2025 | |
| Depuy Synthes Sales INC. | $77.07 | 2022-2024 | Monovisc, Orthovisc |
| Genzyme Corporation | $76.54 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $71.44 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Bioventus LLC | $62.56 | 2021-2025 | Durolane |
| Sandoz INC. | $54.73 | 2024-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $33.95 | 2023-2024 | Strensiq |
| Organon LLC | $31.69 | 2023 | Renflexis, Hadlima |
| Sanofi-Aventis U.S. LLC | $26.45 | 2022 | |
| Medtronic, INC. | $22.89 | 2023 | Kyphon Express II Kyphopak Tray |
| Biotronik Nro, INC. | $21.49 | 2024 | Prospera |
| Almatica Pharma LLC | $16.89 | 2025 | Teriparatide |
| Fresenius Kabi USA, LLC | $16.77 | 2025 | |
| Pacira Therapeutics, INC. | $16.24 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.99 | 2023 | Exparel, Iovera, Zilretta |
| Genentech USA, INC. | $15.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Zacour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.